National Institutes of Health
Turning Discovery Into Health

ManNAc for Podocyte Diseases (NCT02639260)

About this study

This research study will test the safety of an experimental drug, **ManNAc**, in individuals with a confirmed primary podocyte disease, that is either **Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN)**. ManNAc is an essential building block of sialic acid, which is reduced in kidneys of many individuals with FSGS, MCD, and MN.

This is the second study to evaluate ManNAc in people with kidney disease and will enroll 15 patients. Participants of this study will receive ManNAc twice daily for 12 weeks:

- The first 4 days and the last 3 days of the study will be spent on an inpatient unit at the NIH Clinical Center so that drug levels and safety parameters can be closely monitored.
- Participants will continue taking ManNAc twice daily at home for a total of 12 weeks.
- There are 2 brief outpatient visits (each lasting 3-6 hours) to the NIH at weeks 2 and 8 after the start of ManNAc, and 1 final outpatient visit two weeks after you stop taking ManNAc. During these visits, drug levels in the blood and urine will be tested as will the drug effects on your body and kidneys.
- Visits include blood draws, urine tests, physical exams and questionnaires.

Am I eligible?

Your eligibility will be determined by several criteria, including:

- The diagnosis FSGS, MCD, or MN has been confirmed in you by a kidney biopsy.
- You are able to commit to the time required for 2 inpatient visits (up to 3 overnights) and 4 short outpatient visits (each ~3-6h) to the NIH Clinical Center in Bethesda.

Compensation

- Participants will be compensated up to $2000
- NIH will assist with travel, lodging and meals.
- NIH Clinical Center does not bill health insurance companies or you for any research or related clinical care received.

For more information, contact us at:
KidneyManNAc@nih.gov